Products
Simridarlimab Biosimilar Bispecific Antibody (CD47 × PD-L1) for Research
Pre-Made Simridarlimab biosimilar, Whole mAb, Anti-CD47;CD274/PD-L1 Antibody: Anti-IAP/OA3/MER6;B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-693-1mg | 1mg | |
| GMP-Bios-ab-693-10mg | 10mg | |
| GMP-Bios-ab-693-100mg | 100mg | |
| GMP-Bios-ab-693-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Simridarlimab biosimilar, Whole mAb, Anti-CD47;CD274/PD-L1 Antibody: Anti-IAP/OA3/MER6;B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibody |
| INN Name | Simridarlimab |
| Target | CD47;PD-L1 |
| Format | Bispecific Mixed mAb/VH-VH-CH2-CH3 |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1;IgG1 |
| VD LC | Kappa;na |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2021 |
| Year Recommended | na |
| Companies | Innovent Biologics |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Development Tech | na |
About target - CD47
1. Protein Leukocyte surface antigen CD47
2. Gene CD47
3. Organism Homo sapiens (Human)
Function
Has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity).
Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.
